What’s Moving These Biotech Stocks? – Novo Nordisk (NVO), Peregrine Pharmaceuticals (PPHM)

Page 1 of 2

Typically, it doesn’t take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst’s remarks, sometimes it’s caused by earnings, or maybe it’s just a technical response. Sometimes the moves are warranted and other times they are not. Therefore, I am looking at several moves to determine if the stocks are presenting value or a value trap.

Novo Nordisk A/S (ADR) (NYSE:NVO)

Stock Rallies on Acquisition Rumors

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) began the session with gains of 7% but then traded lower to maintain gains of 3% on Monday. The gains were caused by news that Sanofi SA (ADR) (NYSE:SNY) is aiming to buy another $500 million worth of shares in the open market. The two companies are already partners, and Sanofi is limited to the size of its investment. Sanofi has already said that it does not wish to purchase a controlling stake but judging the by the performance of the stock, investors seem to believe that Sanofi might be preparing for an acquisition offer. Regeneron does look expensive to the naked eye, but is consistent with that of other companies that have approved Orphan drugs and others in its pipeline. The company’s growing fast and is much more stable than others with the same valuation. Therefore, I think the stock might be worth buying on this news.

A Volatile Stock Rallies for No Reason

After a volatile year, shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) traded higher by 5% on Monday. The stock rallied on no news but continues to trade in a steady range. At this point, I don’t trust the company. First, there were problems with the clinical study then the study was less affected than thought. There seems to be a lot of inconsistencies, therefore if data is positive for Bavituximab then I would rather pay a higher premium later then buy for a discount now.

Investors Take Profits & Stock Creates Value

European drug maker Novo Nordisk A/S (ADR) (NYSE:NVO) fell 14% on Monday after federal regulators asked for more testing for its diabetes drug. Now, I understand that a diabetes drug has sales potential in the billions, probably over $2 billion. However, this is a massive company that has several drugs that focus on the treatment of diabetes. The company has more than $13.5 billion in revenue and is growing by 15% year-over-year. Therefore, I think the pullback is a great opportunity. The stock had been trading at all-time highs, and it appears that the loss is more of a technical pullback from the stock having two decades of nothing but gains. I would buy on this news.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!